4-(Furan-2-yl)-10-[2-(7-nitro-1,2,4,5-tetrahydro-3-benzazepin-3-yl)ethyl]-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine | 540535-31-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 4-(Furan-2-yl)-10-[2-(7-nitro-1,2,4,5-tetrahydro-3-benzazepin-3-yl)ethyl]-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine
• CAS: 540535-31-7
• 化学式: C₂₂H₂₁N₉O₃
• 分子量: 459.467
• InChiKey: FWZQSNQBDAECAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  149
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-(5-amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl)ethyl 4-methylbenzenesulfonate 、 7-硝基-2,3,4,5-四氢-1H-苯并[d]氮杂卓 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-(Furan-2-yl)-10-[2-(7-nitro-1,2,4,5-tetrahydro-3-benzazepin-3-yl)ethyl]-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine
  参考文献：
  名称：

  Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

  摘要：

  SCH 58261 is a reported adenosine A(2A) receptor antagonist which is active in rat in vivo models of Parkinson's Disease upon ip administration. However, it has poor selectivity versus the A(1) receptor and does not demonstrate oral activity. Quinoline analogs have improved upon the selectivity and pharmacokinetics of SCH 58261, but were difficult to handle due to poor aqueous solubility. We report the design and synthesis of fused heterocyclic analogs of SCH 58261 with aqueous solubility as well as improved A(2A) receptor binding selectivity and pharmacokinetic properties. In particular, the tetrahydronaphthyridine 4s has excellent A(2A) receptor in vitro binding affinity and selectivity, is active orally in a rat in vivo model of Parkinson's Disease, and has aqueous solubility of 100 mu M at physiological pH. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.069

文献信息

• [EN] ADENOSINE A¿2a< RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR A2A D'ADENOSINE
  申请人：SCHERING CORP

  公开号：WO2003048165A1

  公开（公告）日：2003-06-12

  Disclosed herein are compounds having the structural formula (A) including pharmaceutically acceptable salts or solvates of said compound, wherein X, Y, Q and R are as defined in the specification; pharmaceutical compositions thereof; methods of treating central nervous system diseases by administering the compound of the present invention to a patient in need of such treatment, and processes for preparing the compound of this invention.

  本文揭示了具有结构式(A)的化合物，包括该化合物的药用可接受盐或溶剂，其中X，Y，Q和R如规范所定义;其制药组合物;通过向需要此类治疗的患者施用本发明的化合物治疗中枢神经系统疾病的方法，以及制备本发明化合物的方法。
• Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists
  作者：Unmesh Shah、Claire M. Lankin、Craig D. Boyle、Samuel Chackalamannil、William J. Greenlee、Bernard R. Neustadt、Mary E. Cohen-Williams、Guy A. Higgins、Kwokei Ng、Geoffrey B. Varty、Hongtao Zhang、Jean E. Lachowicz

  DOI：10.1016/j.bmcl.2008.05.069

  日期：2008.7

  SCH 58261 is a reported adenosine A(2A) receptor antagonist which is active in rat in vivo models of Parkinson's Disease upon ip administration. However, it has poor selectivity versus the A(1) receptor and does not demonstrate oral activity. Quinoline analogs have improved upon the selectivity and pharmacokinetics of SCH 58261, but were difficult to handle due to poor aqueous solubility. We report the design and synthesis of fused heterocyclic analogs of SCH 58261 with aqueous solubility as well as improved A(2A) receptor binding selectivity and pharmacokinetic properties. In particular, the tetrahydronaphthyridine 4s has excellent A(2A) receptor in vitro binding affinity and selectivity, is active orally in a rat in vivo model of Parkinson's Disease, and has aqueous solubility of 100 mu M at physiological pH. (C) 2008 Elsevier Ltd. All rights reserved.